NHGRI logo

The National Human Genome Research Institute funded the Centers for Mendelian Genomics (CMG) in 2011 with the charge to discover as many genes underlying human Mendelian disorders as possible. In doing so, the CMGs will define the state-of-the-art study designs and methods to find the variants and genes underlying Mendelian disorders.

Overview

The discovery of the genes and genetic variants that underlie human Mendelian disorders is of significant biomedical relevance. The knowledge of those genes and variants will facilitate rapid and accurate diagnosis of patients with Mendelian disorders and may lead to new therapeutic approaches. This knowledge can also lend insight into the common or more complex phenotypes that involve similar genes, pathways, and phenotypes.

While the genetic basis of more than 5,000 Mendelian disorders has been determined so far, many more Mendelian disorders and their underlying genetic basis have yet to be discovered. Recent advances in genomics and bioinformatics have enabled the discovery of the genetic basis of Mendelian disorders using genome-wide approaches, which are more rapid and cost-effective than previous methods such as linkage mapping and candidate gene approaches.

The CMGs aim to make major contributions to the discovery of the genetic basis of Mendelian disorders in two principle ways. Primarily, they will leverage genome-wide sequencing technology and other complementary genomic approaches to discover the genetic basis that underlies Mendelian traits across the spectrum of Mendelian inheritance patterns. Further, they will accelerate discovery across the field of human genetics by disseminating the knowledge and effective approaches obtained over the award period. The CMG will accomplish this through outreach to individual investigators and coordination with other rare disease programs worldwide.

The CMG are co-funded by the National Human Genome Research Institute, the National Heart, Lung, and Blood Institute and the National Eye Institute. More information on the CMGs, including publications and opportunities for collaboration, can be found on the Coordinating Center managed website: www.mendelian.org.

Please note that the CMG are a research program do not provide treatment or other clinical advice. Please visit the Center links above to seek opportunities for collaboration.

  • Overview

    The discovery of the genes and genetic variants that underlie human Mendelian disorders is of significant biomedical relevance. The knowledge of those genes and variants will facilitate rapid and accurate diagnosis of patients with Mendelian disorders and may lead to new therapeutic approaches. This knowledge can also lend insight into the common or more complex phenotypes that involve similar genes, pathways, and phenotypes.

    While the genetic basis of more than 5,000 Mendelian disorders has been determined so far, many more Mendelian disorders and their underlying genetic basis have yet to be discovered. Recent advances in genomics and bioinformatics have enabled the discovery of the genetic basis of Mendelian disorders using genome-wide approaches, which are more rapid and cost-effective than previous methods such as linkage mapping and candidate gene approaches.

    The CMGs aim to make major contributions to the discovery of the genetic basis of Mendelian disorders in two principle ways. Primarily, they will leverage genome-wide sequencing technology and other complementary genomic approaches to discover the genetic basis that underlies Mendelian traits across the spectrum of Mendelian inheritance patterns. Further, they will accelerate discovery across the field of human genetics by disseminating the knowledge and effective approaches obtained over the award period. The CMG will accomplish this through outreach to individual investigators and coordination with other rare disease programs worldwide.

    The CMG are co-funded by the National Human Genome Research Institute, the National Heart, Lung, and Blood Institute and the National Eye Institute. More information on the CMGs, including publications and opportunities for collaboration, can be found on the Coordinating Center managed website: www.mendelian.org.

    Please note that the CMG are a research program do not provide treatment or other clinical advice. Please visit the Center links above to seek opportunities for collaboration.

Funding Opportunities

Active
  • Mendelian Genomics Research Centers (U01 - Clinical Trial Optional)
    RFA-HG-20-007
    Application Due Date(s): April 15, 2020
    Expiration Date: April 16, 2020

     
  • Mendelian Genomics Data Coordinating Center (U24 Clinical Trial Not Allowed)
    RFA-HG-20-008
    Application Due Date(s): April 15, 2020
    Expiration Date: April 16, 2020
Expired
  • Funding Opportunities
    Active
    • Mendelian Genomics Research Centers (U01 - Clinical Trial Optional)
      RFA-HG-20-007
      Application Due Date(s): April 15, 2020
      Expiration Date: April 16, 2020

       
    • Mendelian Genomics Data Coordinating Center (U24 Clinical Trial Not Allowed)
      RFA-HG-20-008
      Application Due Date(s): April 15, 2020
      Expiration Date: April 16, 2020
    Expired

Program Staff

Lisa Chadwick
Lisa H. Chadwick, Ph.D.
  • Program Director
  • Division of Genome Sciences
Chris Wellington, B.S.
Chris Wellington, B.S.
  • Program Director, Computational Genomics and Data Science
  • Office of Genomic Data Science

Last updated: January 9, 2023